Geneseq Biosciences is an R&D-stage biotechnology company, based in Melbourne, Australia.

We specialise in using genomics, machine learning and AI to improve the early and accurate diagnosis of cancer, predict treatment response and monitor patient outcome.


  1. Development and validation of a plasma-based melanoma biomarker suitable for clinical use. British Journal of Cancer, 2018. 118(6): p. 857-866.
  2. A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response. Melanoma Research, 2019. 29(1): p. 19-22.
  3. Characterisation and validation of Mel38; A multi-tissue microRNA signature of cutaneous melanoma. PLoS One, 2019. 14(2): p. e0211504.
  4. Translation of a circulating microRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision. Biomarkers In Medicine, 2021.
  5. Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma. British Journal of Dermatology, 2023, ljad137.